Bayer BP donates Kogenate FS to World Federation of Hemophilia

Published: 28-Jun-2004

Bayer HealthCare LLC, Biological Products Division (Bayer BP), is donating more than 12.2 million units of Kogenate FS (Antihemophilic Factor [Recombinant], Formulated with Sucrose) to the World Federation of Hemophilia (WFH) for distribution in developing countries.


Bayer HealthCare LLC, Biological Products Division (Bayer BP), is donating more than 12.2 million units of Kogenate FS (Antihemophilic Factor [Recombinant], Formulated with Sucrose) to the World Federation of Hemophilia (WFH) for distribution in developing countries.

The donated Kogenate FS has an approximate market value of US$9.3m and will be used to assist the WFH with hemophilia care in 27 countries around the world. The product will be used for emergency life-saving situations or for patients who have been awaiting necessary surgical and dental procedures.

'This contribution of 12.2m units will help alleviate the treatment needs of several thousand people with hemophilia around the world,' said WFH president Brian O'Mahony. 'In countries with low gross national income, many with hemophilia live undiagnosed or untreated. Our ability to provide free product has proven to be a critical success factor for improving and sustaining care in these countries.'

Bayer BP continues to be a major supporter of WFH initiatives such as World Hemophilia Day, and the International External Quality Assessment Scheme (IEQAS), a new program promoting improved standards of laboratory performance and practice in hemophilia treatment centres worldwide. Additionally, it continues to support the WFH's Global Alliance for Progress (GAP) initiative in hemophilia, a project designed to greatly increase the diagnosis and treatment of hemophilia in up to 40 developing countries over the next 10 years.

  

You may also like